Business
Quest PharmaTech Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and the U.S.
TSX Venture: QPT EDMONTON, Jan. 22, 2013 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT) (...
About this update from Quest Pharmatech Inc.
[{"type":"text","content":"\n\n\n\n\n\nTSX Venture: QPT\n\n\nEDMONTON, Jan. 22, 2013 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT)\n (\"Quest\" or the \"Company\"), a pharmaceutical company developing and\n commercializing products for the treatment of cancer, announces that it\n has achieved 50% accrual having enrolled the 40th patient in its ongoing 80 patient Phase II Oregovomab front-line\n chemo-immunotherapy clinical trial in Italy and the U.S.\n\n\nThe objective of this study is to confirm that optimally dosed\n oregovomab in combination with standard front-line chemotherapy for\n advanced ovarian cancer will generate an improved immune and clinical\n response, as seen in preliminary phase II studies, and permit the best\n design of a definitive phase III program to follow. Currently, there\n are 8 clinical trial centers in Italy enrolling patients, with\n Professor Roberto Angioli at Policlinico Universitario Campus\n Bio-Medico Di Roma acting as the study chair. The Company is adding\n three additional centers in the U.S., to the two active U.S. sites,\n through the COGI (Cooperative Ovarian Cancer Group for Immunotherapy)\n clinical trials group, under the leadership of Professor Jonathan Berek\n at the Stanford Women's Cancer Center, Stanford Cancer Institute.\n\n\n\"We are excited to reach the mid-point in patient enrollment for this\n pivotal 80 patient clinical trial\", said Madi R. Madiyalakan, Ph.D.,\n Chief Executive Officer for Quest. \"With 13 centers currently\n participating in the trial, we are hopeful that we will achieve full\n patient enrollment within this year.  This program not only is\n evaluating the latest concepts of combination chemo-immunotherapy for\n ovarian cancer, but is also providing critical data to facilitate the\n pending clinical development of additional cancer antibody\n immunotherapeutics within our technology pipeline.\"\n\n\nAbout Quest PharmaTech Inc.\n\n\nQuest is a publicly traded, Alberta-based biotechnology company\n committed to the development and commercialization of oncology product\n candidates for the treatment of cancer by combining immunotherapeutic\n antibodies with chemotherapy, photodynamic therapy or immunoadjuvants.\n\n\nQuest's technology platform includes a series of monoclonal antibodies\n that target several cancer markers such as CA125, MUC1, PSA, CA19.9 and\n TAG72; and propri...